Crinetics Pharmaceuticals (CRNX) Q3 2024 earnings summary

Executive summary

• Submitted NDA for paltusotine for acromegaly in September 2024; FDA notification expected December 2024 and potential launch in 2025, with European MAA submission planned for 2025.

• Advanced multiple clinical and preclinical programs, including atumelnant in Phase 2 for CAH and Cushing's disease, and four new drug candidates in IND-enabling studies, including the NDC platform.

• Positive topline results from Phase 3 trials for paltusotine and Phase 2 for atumelnant; Phase 3 trial protocol for carcinoid syndrome finalized with FDA feedback.

• Raised significant capital through public offerings and private placements, including a $575M public equity offering, strengthening liquidity for R&D and commercialization.

• Strategic partnership formed between Radionetics and Eli Lilly, with $140M upfront and $1B acquisition option.

Financial highlights

• Ended Q3 2024 with $862.7M in cash and investments; post-offering pro forma cash totals $1.4B.

• Net loss for Q3 2024 was $76.8M, up from $57.5M YoY; net loss for nine months ended September 30, 2024, was $217.8M.

• R&D expenses rose to $61.9M (from $43.8M YoY); G&A expenses increased to $25.9M (from $15.5M YoY).

• No revenue in Q3 2024, compared to $0.3M in Q3 2023; revenue for nine months ended September 30, 2024, was $1.0M.

• Completed $575M public equity offering in October 2024.

Outlook and guidance

• Cash runway projected to fund operations into 2029, including commercialization and multiple late-stage trials.

• Anticipates NDA acceptance for paltusotine in December 2024 and launch in 2025; Phase 3 for carcinoid syndrome and additional IND filings expected in 2025.

• Expects increased R&D and SG&A expenses as pipeline advances and commercial launch preparations continue.

• Updated financial guidance to be provided in Q1 2025.